A Phase 3 interventional study of Evobrutinib and Avonex® in Relapsing-remitting Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 38th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 200 across the 21 interventional studies, 150 across the 19 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
Inclusion Criteria: - Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018) - Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization - Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Baseline. Participants with an EDSS score \<= 2 at Screening are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years - Participants are neurologically stable for >= 30 days prior to both screening and baseline - Female participants must be neither pregnant nor breast-feeding and must lack , as defined by either: or surgically sterile or use an effective method of for the duration of the study - Participants have given written prior to any study-related procedure - Other protocol defined inclusion criteria could apply Exclusion Criteria: - Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b). Participants with secondary progressive MS without evidence of relapse.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
Drug: Evobrutinib · Drug: Avonex® matched Placebo
Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
Drug: Avonex® · Drug: Evobrutinib matched Placebo
Participants received evobrutinib twice daily (BID).
Also known as: M2951
Participants received avonex® IM injection once a week.
Participants received IM injection of placebo matched to Avonex® once a week.
Participants received placebo matched to evobrutinib twice a day.
Annualized Relapse Rate (ARR)
The annualized relapse rate at 96 weeks was to be calculated based on qualified relapses. A qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to MS. The relapse should be accompanied by an increase of 0.5 points or more on Expanded Disability Status Scale (EDSS), or 2 points increase on one of the Functional System Scores (FSS), or 1 point increase on at least two of the FSS. The increase in FSS scores must be related to the neurological symptoms which were reported as new or worsening.
Time frame: At Week 96
Time to First Occurrence of 12-Week Confirmed Expanded Disability Status Scale (EDSS) Progression
EDSS is an ordinal scale in half-point increments that measures disability in participants with MS. EDSS progression is defined as an increase of 1 point or more from Baseline EDSS score when the Baseline score is 5.0 or less, and an increase of 0.5 points or more when the Baseline score is 5.5 or greater. Time to first occurrence of 12-week confirmed EDSS progression is defined as the time from randomization to the first EDSS progression event that was confirmed at a regularly scheduled visit at least 12 weeks later.
Time frame: Baseline up to 96 weeks
Time to First Occurrence of 24-Week Confirmed Expanded Disability Status Scale (EDSS) Progression
EDSS is an ordinal scale in half-point increments that measures disability in participants with MS. EDSS progression is defined as an increase of 1 point or more from Baseline EDSS score when the Baseline score is 5.0 or less, and an increase of 0.5 points or more when the Baseline score is 5.5 or greater. Time to first occurrence of 24-week confirmed EDSS progression is defined as the time from randomization to the first EDSS progression event that was confirmed at a regularly scheduled visit at least 24 weeks later.
Time frame: Baseline up to 96 weeks
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Short Form Score at Week 96
The PROMIS PF Short Form is specific to measuring the physical function domain of MS patients, with each item on the form scored on a T-score metric. Higher scores indicate higher PF. Change from baseline at Week 96 is the difference between the PROMIS PF scores at 96 weeks and at baseline.
Time frame: Baseline, Week 96
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Fatigue Score at Week 96
The PROMIS Fatigue Short Form is specific to measuring the fatigue domain of MS patients, with each item on the form scored on a T-score metric. Higher scores indicate higher fatigue. Change from baseline at Week 96 is the difference between the PROMIS Fatigue scores at 96 weeks and at baseline.
Time frame: Baseline, Week 96
Total Number of Gadolinium-Enhancing (Gd+) Time Constant 1 (T1) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96
Total number of Gd+ T1 lesions was to be assessed using magnetic resonance imaging (MRI).
Time frame: At Week 24, 48 and 96
Total Number of New or Enlarging Time Constant 2 (T2) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96
Total number of new or enlarging T2 lesions was to be assessed using magnetic resonance imaging (MRI).
Time frame: At Week 24, 48 and 96
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. TEAE is an AE that started after study drug treatment; or if the event was continuous from baseline and was serious, related to study drug, or resulted in death, discontinuation, interruption or reduction of study therapy. TEAEs includes both serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug induced, non-infectious, non-alcoholic and immune-mediated) infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.
Time frame: Baseline up to 235 days
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
TEAE is an AE that started after study drug treatment; or if the event was continuous from baseline and was serious, related to investigational medicinal product (IMP), or resulted in death, discontinuation, interruption or reduction of study therapy. Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs based on severity were reported.
Time frame: Baseline up to 235 days
Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
DBP and SBP were measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
Time frame: At Day 1, 83, 125 and 155
Vital Signs: Pulse Rate
Pulse rate was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
Time frame: At Day 1, 83, 125 and 155
Vital Signs: Respiratory Rate
Respiration rate was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
Time frame: At Day 1, 83, 125 and 155
Vital Signs: Temperature
Temperature was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
Time frame: At Day 1, 83, 125 and 155
Vital Signs: Weight
Time frame: At Day 1, 83, 125 and 155
Number of Participants With Abnormal Lab Values
The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, coagulation, biochemistry and urinalysis.
Time frame: Baseline up to 235 days
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals.
Time frame: Baseline up to 235 days
Absolute Concentrations of Immunoglobulin (Ig) A Level
Absolute concentrations of Immunoglobulin (Ig) A was reported.
Time frame: At Day 1, 83, 125 and 155
Absolute Concentrations of Immunoglobulin (Ig) E Level
Absolute concentrations of Immunoglobulin (Ig) E was reported.
Time frame: At Day 1, 83, 125 and 155
Absolute Concentrations of Immunoglobulin (Ig) G Level
Absolute concentrations of Immunoglobulin (Ig) G was reported.
Time frame: At Day 1, 83, 125 and 155
Absolute Concentrations of Immunoglobulin (Ig) M Level
Absolute concentrations of Immunoglobulin (Ig) M was reported.
Time frame: At Day 1, 83, 125 and 155
Change From Baseline in Immunoglobulin (Ig) A Level
Change from baseline in immunoglobulin (Ig) A level was reported.
Time frame: At Day 1, 83, 125 and 155
Change From Baseline in Immunoglobulin (Ig) E Level
Change from baseline in immunoglobulin (Ig) E level was reported.
Time frame: At Day 1, 83, 125 and 155
Change From Baseline in Immunoglobulin (Ig) G Level
Change from baseline in immunoglobulin (Ig) G level was reported.
Time frame: At Day 1, 83, 125 and 155
Change From Baseline in Immunoglobulin (Ig) M Level
Change from baseline in immunoglobulin (Ig) M level was reported.
Time frame: At Day 1, 83, 125 and 155
| Milestone | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Started | 2 | 1 |
| Completed | 0 | 0 |
| Not completed | 2 | 1 |
| Withdrew: Study termination | 2 | 1 |
The annualized relapse rate at 96 weeks was to be calculated based on qualified relapses. A qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to MS. The relapse should be accompanied by an increase of 0.5 points or more on Expanded Disability Status Scale (EDSS), or 2 points increase on one of the Functional System Scores (FSS), or 1 point increase on at least two of the FSS. The increase in FSS scores must be related to the neurological symptoms which were reported as new or worsening.
No measurements were reported for this outcome.
EDSS is an ordinal scale in half-point increments that measures disability in participants with MS. EDSS progression is defined as an increase of 1 point or more from Baseline EDSS score when the Baseline score is 5.0 or less, and an increase of 0.5 points or more when the Baseline score is 5.5 or greater. Time to first occurrence of 12-week confirmed EDSS progression is defined as the time from randomization to the first EDSS progression event that was confirmed at a regularly scheduled visit at least 12 weeks later.
No measurements were reported for this outcome.
EDSS is an ordinal scale in half-point increments that measures disability in participants with MS. EDSS progression is defined as an increase of 1 point or more from Baseline EDSS score when the Baseline score is 5.0 or less, and an increase of 0.5 points or more when the Baseline score is 5.5 or greater. Time to first occurrence of 24-week confirmed EDSS progression is defined as the time from randomization to the first EDSS progression event that was confirmed at a regularly scheduled visit at least 24 weeks later.
No measurements were reported for this outcome.
The PROMIS PF Short Form is specific to measuring the physical function domain of MS patients, with each item on the form scored on a T-score metric. Higher scores indicate higher PF. Change from baseline at Week 96 is the difference between the PROMIS PF scores at 96 weeks and at baseline.
No measurements were reported for this outcome.
The PROMIS Fatigue Short Form is specific to measuring the fatigue domain of MS patients, with each item on the form scored on a T-score metric. Higher scores indicate higher fatigue. Change from baseline at Week 96 is the difference between the PROMIS Fatigue scores at 96 weeks and at baseline.
No measurements were reported for this outcome.
Total number of Gd+ T1 lesions was to be assessed using magnetic resonance imaging (MRI).
No measurements were reported for this outcome.
Total number of new or enlarging T2 lesions was to be assessed using magnetic resonance imaging (MRI).
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. TEAE is an AE that started after study drug treatment; or if the event was continuous from baseline and was serious, related to study drug, or resulted in death, discontinuation, interruption or reduction of study therapy. TEAEs includes both serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug induced, non-infectious, non-alcoholic and immune-mediated) infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.
| Participants | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants with AESIs | 0 | 0 |
| Participants with TEAEs | 2 | 1 |
| Participants with Serious TEAEs | 0 | 0 |
TEAE is an AE that started after study drug treatment; or if the event was continuous from baseline and was serious, related to investigational medicinal product (IMP), or resulted in death, discontinuation, interruption or reduction of study therapy. Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs based on severity were reported.
| Participants | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Grade 1 | 2 | 0 |
| Grade 2 | 0 | 1 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Grade 5 | 0 | 0 |
DBP and SBP were measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
| Millimeters of mercury (mmHg) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants 1 - DBP: Day 1 | — | 82 |
| Participants 1 - DBP: Day 83 | — | 87 |
| Participants 1 - DBP: Day 125 | — | 80 |
| Participants 1 - DBP: Day 155 | — | 75 |
| Participants 1 - SBP: Day 1 | — | 112 |
| Participants 1 - SBP: Day 83 | — | 120 |
| Participants 1 - SBP: Day 125 | — | 118 |
| Participants 1 - SBP: Day 155 | — | 109 |
| Participants 2 - DBP: Day 1 | 84 | — |
| Participants 2 - DBP: Day 83 | 77 | — |
| Participants 2 - DBP: Day 125 | 84 | — |
| Participants 2 - DBP: Day 155 | 90 | — |
| Participants 2 - SBP: Day 1 | 124 | — |
| Participants 2 - SBP: Day 83 | 133 | — |
| Participants 2 - SBP: Day 125 | 138 | — |
| Participants 2 - SBP: Day 155 | 137 | — |
| Participant 3 - DBP: Day 1 | 65 | — |
| Participants 3 - DBP: Day 125 | 76 | — |
| Participants 3 - SBP: Day 1 | 101 | — |
| Participant 3 - SBP: Day 125 | 117 | — |
Pulse rate was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
| Beats per minute | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants 1 - Pulse rate: Day 1 | — | 71 |
| Participants 1 - Pulse rate: Day 83 | — | 69 |
| Participants 1 - Pulse rate: Day 125 | — | 72 |
| Participants 1 - Pulse rate: Day 155 | — | 75 |
| Participants 2 - Pulse rate: Day 1 | 71 | — |
| Participants 2 - Pulse rate: Day 83 | 66 | — |
| Participants 2 - Pulse rate: Day 125 | 82 | — |
| Participants 2 - Pulse rate: Day 155 | 82 | — |
| Participant 3 - Pulse rate: Day 1 | 76 | — |
| Participants 3 - Pulse rate: Day 125 | 75 | — |
Respiration rate was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
| Breaths Per Minute | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants 1 - Respiratory rate: Day 1 | — | 20 |
| Participants 1 - Respiratory rate: Day 83 | — | 18 |
| Participants 1 - Respiratory rate: Day 125 | — | 18 |
| Participants 1 - Respiratory rate: Day 155 | — | 20 |
| Participants 2 - Respiratory rate: Day 1 | 18 | — |
| Participants 2 - Respiratory rate: Day 83 | 20 | — |
| Participants 2 - Respiratory rate: Day 125 | 18 | — |
| Participants 2 - Respiratory rate: Day 155 | 20 | — |
| Participant 3 - Respiratory rate: Day 1 | 18 | — |
| Participants 3 - Respiratory rate: Day 125 | 18 | — |
Temperature was measured in semi-supine position after 5 minutes rest for the participants at indicated time points.
| Degree celsius | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants 1: Day 1 | — | 35.7 |
| Participants 1: Day 83 | — | 36.4 |
| Participants 1: Day 125 | — | 36.9 |
| Participants 1: Day 155 | — | 36.4 |
| Participants 2: Day 1 | 36.9 | — |
| Participants 2: Day 83 | 36.7 | — |
| Participants 2: Day 125 | 36.9 | — |
| Participants 2: Day 155 | 36.8 | — |
| Participant 3: Day 1 | 36.5 | — |
| Participants 3: Day 125 | 37.0 | — |
| kilogram (kg) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participants 1: Day 1 | — | 75.7 |
| Participants 1: Day 83 | — | 74.9 |
| Participants 1: Day 125 | — | 77.3 |
| Participants 1: Day 155 | — | 77.2 |
| Participants 2: Day 1 | 89.0 | — |
| Participants 2: Day 83 | 89.0 | — |
| Participants 2: Day 125 | 92.2 | — |
| Participants 2: Day 155 | 92.1 | — |
| Participant 3: Day 1 | 40.8 | — |
| Participants 3: Day 125 | 40.3 | — |
The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, coagulation, biochemistry and urinalysis.
| Participants | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Number of Participants With Abnormal Lab Values | 0 | 0 |
ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals.
| Participants | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 |
Absolute concentrations of Immunoglobulin (Ig) A was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 1 | — | 2.09 |
| Participant 1: Day 83 | — | 2.64 |
| Participant 1: Day 125 | — | 2.64 |
| Participant 1: Day 155 | — | 2.78 |
| Participant 2: Day 1 | 1.64 | — |
| Participant 2: Day 83 | 1.85 | — |
| Participant 2: Day 125 | 2.2 | — |
| Participant 2: Day 155 | 2.15 | — |
| Participant 3: Day 1 | 2.09 | — |
| Participant 3: Day 125 | 1.84 | — |
Absolute concentrations of Immunoglobulin (Ig) E was reported.
| International unit per milliliter(IU/mL) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 1 | — | 61 |
| Participant 1: Day 83 | — | 108 |
| Participant 1: Day 125 | — | 55.2 |
| Participant 1: Day 155 | — | 71.9 |
| Participant 2: Day 1 | 10.7 | — |
| Participant 2: Day 83 | 12.3 | — |
| Participant 2: Day 125 | 14.9 | — |
| Participant 2: Day 155 | 11.4 | — |
| Participant 3: Day 1 | 27.6 | — |
| Participant 3: Day 125 | 23.5 | — |
Absolute concentrations of Immunoglobulin (Ig) G was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 1 | — | 16.49 |
| Participant 1: Day 83 | — | 21.77 |
| Participant 1: Day 125 | — | 19.34 |
| Participant 1: Day 155 | — | 19.62 |
| Participant 2: Day 1 | 9.46 | — |
| Participant 2: Day 83 | 10.26 | — |
| Participant 2: Day 125 | 11.23 | — |
| Participant 2: Day 155 | 11.18 | — |
| Participant 3: Day 1 | 12.52 | — |
| Participant 3: Day 125 | 11.41 | — |
Absolute concentrations of Immunoglobulin (Ig) M was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 1 | — | 0.97 |
| Participant 1: Day 83 | — | 1.47 |
| Participant 1: Day 125 | — | 1.35 |
| Participant 1: Day 155 | — | 1.43 |
| Participant 2: Day 1 | 1.08 | — |
| Participant 2: Day 83 | 0.84 | — |
| Participant 2: Day 125 | 0.78 | — |
| Participant 2: Day 155 | 1 | — |
| Participant 3: Day 1 | 2.22 | — |
| Participant 3: 125 | 1.91 | — |
Change from baseline in immunoglobulin (Ig) A level was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 83 | — | 0.55 |
| Participant 1: Day 125 | — | 0.55 |
| Participant 1: Day 155 | — | 0.69 |
| Participant 2: Day 83 | 0.21 | — |
| Participant 2: Day 125 | 0.56 | — |
| Participant 2: Day 155 | 0.51 | — |
| Participant 3: Day 125 | -0.25 | — |
Change from baseline in immunoglobulin (Ig) E level was reported.
| International unit per milliliter(IU/mL) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 83 | — | 47 |
| Participant 1: Day 125 | — | -5.8 |
| Participant 1: Day 155 | — | 10.9 |
| Participant 2: Day 83 | 1.6 | — |
| Participant 2: Day 125 | 4.2 | — |
| Participant 2: Day 155 | 0.7 | — |
| Participant 3: Day 125 | -4.1 | — |
Change from baseline in immunoglobulin (Ig) G level was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 83 | — | 5.28 |
| Participant 1: Day 125 | — | 2.85 |
| Participant 1: Day 155 | — | 3.13 |
| Participant 2: Day 83 | 0.8 | — |
| Participant 2: Day 125 | 1.77 | — |
| Participant 2: Day 155 | 1.72 | — |
| Participant 3: Day 125 | -1.11 | — |
Change from baseline in immunoglobulin (Ig) M level was reported.
| grams per liter (g/L) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Participant 1: Day 83 | — | 0.5 |
| Participant 1: Day 125 | — | 0.38 |
| Participant 1: Day 155 | — | 0.46 |
| Participant 2: Day 83 | -0.24 | — |
| Participant 2: Day 125 | -0.3 | — |
| Participant 2: Day 155 | -0.08 | — |
| Participant 3: Day 125 | -0.31 | — |
Collected over Baseline up to 235 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Evobrutinib + Avonex® Matched Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Active Comparator: Avonex® + Evobrutinib Matched Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo |
|---|---|---|
| Neutrophil count decreasedInvestigations | 0/2 | 1/1 |
| Tension headacheNervous system disorders | 0/2 | 1/1 |
| Abdominal painGastrointestinal disorders | 0/2 | 1/1 |
| VomitingGastrointestinal disorders | 0/2 | 1/1 |
| Drug eruptionGeneral disorders | 1/2 | 0/1 |
| Influenza like illnessGeneral disorders | 1/2 | 0/1 |
| Pain in jawMusculoskeletal and connective tissue disorders | 1/2 | 0/1 |
| ParaesthesiaNervous system disorders | 1/2 | 0/1 |
| Tinea crurisSkin and subcutaneous tissue disorders | 1/2 | 0/1 |
| PetechiaeSkin and subcutaneous tissue disorders | 1/2 | 0/1 |
| Age, Categorical(Participants) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 3 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Experimental: Evobrutinib + Avonex® Matched Placebo | Active Comparator: Avonex® + Evobrutinib Matched Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 2 | 0 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html
Ran from Aug 2019 to primary completion in Apr 2020, 7 months.
Results were first posted in Aug 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Multiple Sclerosis, Relapsing-Remitting →
EMD Serono Research & Development Institute, Inc. →